Prophylix Pharma AS
Prophylix Pharma AS
Video
Prophylix Pharma

is aiming to develop a safe new treatment that prevents excessive bleeding in fetuses and newborns caused by FNAIT. Today, such bleedings may cause life-long disabilities or death.

Read more

FNAIT

Some excessive bleedings in foetuses and neonates occur because there are too few platelets to stop the bleeding. This may be caused by Foetal Neonatal Alloimmune Thrombocytopenia (FNAIT).

Read more

The PROFNAIT project

is an EU-funded collaboration between Prophylix Pharma, Larix A/S and leading hospitals, blood banks and universities in Europe aimed at developing a prophylaxis against FNAIT.

Read more